Precision Optics (POCI) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
16 Apr, 2026Business overview and strategy
Vertically integrated optics company leveraging proprietary micro-optics and imaging technologies for healthcare and defense/aerospace sectors, offering services from concept to mass manufacture.
Over 40 years of growth, with expansion into medical devices, defense, telecom, and recent acquisitions to broaden capabilities.
Business model emphasizes early-stage collaboration with key clients, robust R&D pipeline, and maintaining IP through internal and customer-funded research.
Focus on micro-optics, 3D imaging, and digital imaging, with a disciplined investment approach and facility expansion to support growth.
Strategic acquisitions and the launch of the Unity Platform aim to accelerate development and commercialization of new products.
Key technologies and markets
Specializes in millimeter-sized cameras and patented opto-mechanical/electronic systems for minimally invasive surgery and defense applications.
One of few global providers of 3D endoscopes, supporting next-gen robotic surgery and advanced imaging systems.
Expertise in digital imaging electronics, especially CMOS-based systems, with full system design capabilities for both single-use and reusable devices.
Main markets include medical devices (e.g., neurosurgery, cardiology, urology, arthroscopy) and aerospace/defense (e.g., UAVs, satellite communications, directed energy weapons).
Financial performance and outlook
Revenue grew from $4.0M in 2017 to $21.0M in 2024, with 2026 guidance of $26M–$28M.
Gross margins have ranged from 24% to 40% over recent years.
Adjusted EBITDA has fluctuated, with recent years showing negative values, but improvements are targeted.
Balance sheet as of 12/31/2025 shows $881K in cash, $4.9M in receivables, $4.3M in inventory, and $9.3M in shareholder equity.
Latest events from Precision Optics
- Revenue and margins surged as new satellite and medical device programs fueled rapid growth.POCI
Lytham Partners Fall 2026 Investor Conference - Record revenue and profitability gains in FY2026 driven by space and medical device growth.POCI
Investor presentation - Record revenue and margin gains, but FY 2027 outlook impacted by satellite order slowdown.POCI
Q4 2026 - Growth accelerates as micro-optics drive expansion in satellite, defense, and single-use endoscopy.POCI
Lytham Partners 2026 Consumer & Technology Investor Summit - Production ramp in medical and satellite optics drives revenue growth and margin recovery.POCI
Planet MicroCap Las Vegas 2026 - Accelerated revenue growth driven by new production programs and robust technology pipeline.POCI
Lytham Partners Spring 2026 Investor Conference - Strong revenue growth, major new orders, and expanding product pipeline drive future prospects.POCI
Corporate presentation - Record Q3 revenue, margin gains, and a $10M+ offering drove raised FY2026 guidance.POCI
Q3 2026 - Revenue and margins fell, but backlog and new contracts support a strong Q4 outlook.POCI
Q3 2025